<main>
<h1>Optistavin helps prolong survival<h2>
	<h4>Optistivan + chemotherapy demonstrated a 28% increase in median overall survival (OS) vs chemo alone<sup>1</sup></h4>
	<div id="graph"></div>
	<p class="graph_footer">Most frequently occuring adverse events grades 3-5: neutropenia 17%, 23%; fatigue 13%, 16%; hypertension 2%, 8% for control + chemo and Optistavin + chemo, respectively</p> 
</main>